Preview

Медицинский Совет

Расширенный поиск

ПРИМЕНЕНИЕ КАНДЕСАРТАНА В КАРДИОЛОГИЧЕСКОЙ ПРАКТИКЕ

https://doi.org/10.21518/2079-701X-2017-7-12-16

Полный текст:

Аннотация

Наиболее значимым фактором риска в развитии сердечно-сосудистых заболеваний, таких как инфаркт миокарда, ишемическая болезнь сердца, хроническая сердечная недостаточность, является артериальная гипертензия (АГ) [1]. Также АГ вносит свой вклад в развитие цереброваскулярных (ишемический или геморрагический инсульт, транзиторная ишемическая атака) и почечных заболеваний (хроническая болезнь почек).

Об авторе

Н. А. Джаиани
Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России
Россия
д.м.н., профессор


Список литературы

1. Рекомендации по лечению артериальной гипертонии ESH/ESC 2013. Российский кардиологический журнал, 2014, 1(105): 14.

2. Burnier M. Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension. Drugs, 2002, 62(1): 21-29.

3. Dzau V et al. Heterogenity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J. Hypertens., 1993, 11(3): 11–18.

4. Jackson EK, Garrison JC: Renin and Angiotensin. In Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th edition. New York: McGraw Hill, 2003: 744.

5. Бова А.А. Место антагонистов рецепторов ангиотензина II в клинической практике. Медицинские новости, 2009, 6: 11-15.

6. Полосьянц О.Б. Cартаны в кардиологической практике. РМЖ, 2008, 11: 1593.

7. Reboldi G, Angeli F, Cavallini C. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. Hypertens, 2008, 26: 1282–1289.

8. Schrader J, Luders S, Kulschewski A. MOsEs study Group. Morbidity and mortality after stroke, epro- sartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOsEs). Stroke, 2005, 36: 1218–1226.

9. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В.. Особенности применения кандесартана в клинической практике. Consilium Medicum, 2016, 01: 54-59.

10. Мартынов А.И., Аветян Н.Г., Гороховская Г.Н., Акатова Е.В., Романовская Г.А. Антигипертензивные и органопротективные эффекты комбинированной терапии ингибитором ангиотензинпревращающего фермента и антагонистом кальция. Consilium Medicum, 2006, 11: 15-20.

11. Остроумова О.Д., Бондарец О.В., Гусева Т.Ф. Преимущества кандесартана в лечении артериальной гипертонии. Системные гипертензии, 2014, 2: 62-66.

12. Zhenfeng Zheng, Huilan Shi, Junya Jia et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst, 2011, 12(3): 365–74.

13. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens, 2012, 34(2): 86–91.

14. Kario K, Ishikawa J, Pickering TJ. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res., 2006, 29(8): 581–587.

15. Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press, 2013, 22(Suppl. 1): 29–37.

16. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens, 2003, 21: 875–86.

17. Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE)-recent analyses. J Hypertens Suppl., 2006, 24(1): 107–114.

18. Sunami E, Nomura K, Nishiyama Y, Katayama Y. Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. J Nippon Med Sch, 2016, 83(6): 272-276.

19. Matsuno Y, Minatoguchi S, Fujiwara H et al. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. Blood Press, 2011, 20(Suppl. 1): 12–9.

20. Escobar C, Barrios V, Calderón A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich), 2008, 10(3): 208–14.

21. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev. Cardiovasc. Ther., 2008: 1195-1201.

22. Cuspidi C, Muiesan ML, Valagussa L еt al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens., 2002, 20: 2293-2300.

23. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H, HIJCREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur. Heart J., 2009, 30: 1203-1212.

24. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Цstergren J, Yusuf S. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362: 759-766.

25. McMurray JJV, Цstergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensinconvertingenzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362: 767-771.

26. Granger CB, McMurray JJV, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensinconvertingenzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003, 362: 772-776.

27. Yusuf S, Pfeffer MA, Swedberg K et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362: 777-781.

28. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am. Heart J., 2006, 152: 86-92.

29. Suzuki T, Nozawa T, Fujii N, Sobajima M, Ohori T, Shida T, Matsuki A, Kameyama T, Inoue H. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coron. Artery Dis., 2011, 22: 352-35.

30. Сиренко Ю.Н., Донченко Н.В. Место кандесартана в современной терапии сердечно-сосудистых заболеваний: обзор доказательств. Артериальная гипертензия, 2011, 4(18): 114–26.

31. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В. Особенности применения кандесартана в клинической практике. Consilium Medicum, 2016, 18(1): 68–73.

32. Burgess E, Muirhead N, de Cotret PR et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol, 2009, 20: 893–900.

33. Mogensen CE, Neldam S, Tikkanen I et al. For the CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 2000, 321: 1440–4.

34. Norris S, Weinstein J, Peterson K, Thakurta S. Drug Class Review. Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers. Drug Effectiveness Review Project. Oregon Health & Science University, 2009.


Просмотров: 231


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)